Medibiofarma — Other · €1M

Navarre biopharma Medibiofarma closed a €1M capital increase subscribed by the founding team together with regional public investor Sodena and Inveready. The funds advance the clinical phase of its three drug candidates — MBF-118 (Crohn's disease), MBF-015 (Huntington's) and MBF-362 (oncology) — towards early licensing deals; no venture stage or lead investor was disclosed.